Literature DB >> 27501401

Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations.

S A Cohen1,2, M C Woodfield1, N Boyle1, Z Stednick1, M Boeckh1,2, S A Pergam3,4,5.   

Abstract

BACKGROUND: Probiotic supplementation has been promoted for numerous health conditions; however, safety in immunosuppressed patients is unknown. We evaluated bloodstream infections (BSIs) caused by common probiotic organisms in hematopoietic cell transplant recipients.
METHODS: All blood culture (BC) results from a cohort of hematopoietic cell transplant recipients transplanted at Fred Hutchinson Cancer Research Center in Seattle, Washington, between 2002 and 2011 were reviewed. Patients with at least 1 positive BC for common probiotic organisms (Lactobacillus species, Bifidobacterium species, Streptococcus thermophilus, and Saccharomyces species) within 1 year post hematopoietic cell transplantation (HCT) were considered cases. Data were collected from center databases, which contain archived laboratory data, patient demographics, and clinical summaries.
RESULTS: A total of 19/3796 (0.5%) patients developed a BSI from one of these organisms within 1 year post HCT; no Bifidobacterium species or S. thermophilus were identified. Cases had a median age of 49 years (interquartile range [IQR]: 39-53), and the majority were allogeneic hematopoietic cell transplant recipients (14/19, 74%). Most positive BCs were Lactobacillus species (18/19) and occurred at a median of 84 days (IQR: 34-127) post transplant. The incidence rate of Lactobacillus bacteremia was 1.62 cases per 100,000 patient-days; the highest rate occurred within 100 days post transplant (3.3 per 100,000 patient-days). Eight patients (44%) were diagnosed with acute graft-versus-host disease of the gut prior to the development of bacteremia. No mortality was attributable to any of these infections.
CONCLUSION: Organisms frequently incorporated in available over-the-counter probiotics are infrequent causes of bacteremia after HCT. Studies evaluating the use of probiotics among high-risk patients are needed.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Lactobacilluszzm321990; bacteremia; fungemia; hematopoietic cell transplant; over-the-counter; probiotic

Mesh:

Substances:

Year:  2016        PMID: 27501401      PMCID: PMC5160044          DOI: 10.1111/tid.12587

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  27 in total

1.  US Food and Drug Administration regulations governing label claims for food products, including probiotics.

Authors:  Leila G Saldanha
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.

Authors:  Arnoldo J Riquelme; Mario A Calvo; Ana M Guzmán; María S Depix; Patricia García; Carlos Pérez; Marco Arrese; Jaime A Labarca
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

Review 3.  Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature.

Authors:  Simone Meini; Raffaele Laureano; Lucia Fani; Carlo Tascini; Angelo Galano; Alberto Antonelli; Gian Maria Rossolini
Journal:  Infection       Date:  2015-05-30       Impact factor: 3.553

4.  Investigation of inpatient probiotic use at an academic medical center.

Authors:  Jacques Simkins; Anna Kaltsas; Brian P Currie
Journal:  Int J Infect Dis       Date:  2012-12-14       Impact factor: 3.623

Review 5.  Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.

Authors:  Aloysius L D'Souza; Chakravarthi Rajkumar; Jonathan Cooke; Christopher J Bulpitt
Journal:  BMJ       Date:  2002-06-08

6.  Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.

Authors:  Mariko Wada; Satoru Nagata; Masahiro Saito; Toshiaki Shimizu; Yuichiro Yamashiro; Takahiro Matsuki; Takashi Asahara; Koji Nomoto
Journal:  Support Care Cancer       Date:  2009-08-14       Impact factor: 3.603

Review 7.  Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.

Authors:  Bradley C Johnston; Stephanie S Y Ma; Joshua Z Goldenberg; Kristian Thorlund; Per O Vandvik; Mark Loeb; Gordon H Guyatt
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

8.  The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation.

Authors:  E J Ladas; M Bhatia; L Chen; E Sandler; A Petrovic; D M Berman; F Hamblin; M Gates; R Hawks; L Sung; M Nieder
Journal:  Bone Marrow Transplant       Date:  2015-11-16       Impact factor: 5.483

9.  Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis.

Authors:  Ludmila Khailova; Daniel N Frank; Jessica A Dominguez; Paul E Wischmeyer
Journal:  Anesthesiology       Date:  2013-07       Impact factor: 7.892

10.  Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.

Authors:  Mary Hickson; Aloysius L D'Souza; Nirmala Muthu; Thomas R Rogers; Susan Want; Chakravarthi Rajkumar; Christopher J Bulpitt
Journal:  BMJ       Date:  2007-06-29
View more
  16 in total

Review 1.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

2.  Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity.

Authors:  Eirin Esaiassen; Erik Hjerde; Jorunn Pauline Cavanagh; Gunnar Skov Simonsen; Claus Klingenberg
Journal:  J Clin Microbiol       Date:  2017-05-10       Impact factor: 5.948

Review 3.  The gut microbiota in transplant patients.

Authors:  Pearlie P Chong; Andrew Y Koh
Journal:  Blood Rev       Date:  2019-08-29       Impact factor: 8.250

Review 4.  Microbiota modification in hematology: still at the bench or ready for the bedside?

Authors:  Christopher J Severyn; Ryan Brewster; Tessa M Andermann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system.

Authors:  Eija Nissilä; François P Douillard; Jarmo Ritari; Lars Paulin; Hanna M Järvinen; Pia Rasinkangas; Karita Haapasalo; Seppo Meri; Hanna Jarva; Willem M de Vos
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

Review 6.  Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation.

Authors:  Daniele Zama; Gianluca Bossù; Davide Leardini; Edoardo Muratore; Elena Biagi; Arcangelo Prete; Andrea Pession; Riccardo Masetti
Journal:  Ther Adv Hematol       Date:  2020-01-20

Review 7.  Microbiota modification in hematology: still at the bench or ready for the bedside?

Authors:  Christopher J Severyn; Ryan Brewster; Tessa M Andermann
Journal:  Blood Adv       Date:  2019-11-12

Review 8.  The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Wei-Te Lei; Chien-Yu Lin; Tzu-Lin Yeh; Pei-Ching Shih; Shu-Jung Liu; Chao-Hsu Lin; Jui-Ming Liu
Journal:  Drug Des Devel Ther       Date:  2018-01-25       Impact factor: 4.162

9.  Lactobacillus rhamnosus Bacteremia in an Immunocompromised Renal Transplant Patient.

Authors:  Selin Sendil; Isha Shrimanker; Qurat Mansoora; John Goldman; Vinod K Nookala
Journal:  Cureus       Date:  2020-02-05

10. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.